key: cord-0942307-kcarnfz2
authors: Nyberg, Tommy; Harman, Katie; Zaidi, Asad; Seaman, Shaun R; Andrews, Nick; Nash, Sophie G; Charlett, Andre; Lopez Bernal, Jamie; Myers, Richard; Groves, Natalie; Gallagher, Eileen; Gharbia, Saheer; Chand, Meera; Thelwall, Simon; De Angelis, Daniela; Dabrera, Gavin; Presanis, Anne M
title: Hospitalisation and mortality risk for COVID-19 cases with SARS-CoV-2 AY.4.2 (VUI-21OCT-01) compared to non-AY.4.2 Delta variant sub-lineages
date: 2022-02-20
journal: J Infect Dis
DOI: 10.1093/infdis/jiac063
sha: 4a25d9c73cf0ca785f867d1fb90549ee232c6873
doc_id: 942307
cord_uid: kcarnfz2

To investigate if the AY.4.2 sub-lineage of the SARS-CoV-2 Delta variant is associated with hospitalisation and mortality risks that differ from non-AY.4.2 Delta risks, we performed a retrospective cohort study of sequencing-confirmed COVID-19 cases in England based on linkage of routine healthcare datasets. Using stratified Cox regression, we estimated adjusted hazard ratios (aHR) of hospital admission (aHR=0.85, 95% CI 0.77-0.94), hospital admission or emergency care attendance (aHR=0.87, 95% CI 0.81-0.94) and COVID-19 mortality (aHR=0.85, 95% CI 0.71-1.03). The results indicate that the risks of hospitalisation and mortality is similar or lower for AY.4.2 compared to cases with other Delta sub-lineages.

M a n u s c r i p t on 20 October 2021 [1] . It is unknown whether AY.4.2 is associated with a differently severe COVID-19 than non-AY.4.2 Delta. We therefore investigated the relative severity of AY.4.2 compared to other Delta cases using a retrospective cohort study.

The study population comprised of COVID-19 cases in England with a first positive specimen between 21 June and 7 November 2021 who were infected with AY.4.2 or a non-AY.4.2 Delta variant based on whole-genome sequencing. Data on these cases were linked to national hospital care and mortality datasets on 1 December 2021. Before the week commencing 21 June, <0.2% of sequencing-confirmed Delta cases had the AY.4.2 sub-lineage [1] ; during the inclusion period the prevalence of AY.4.2 among new sequencing-confirmed cases increased from 0.2% to 15% (Supplementary Figure 1) . The data linkage, inclusion criteria, outcome and confounder data sources and definitions, and the analysis strategy have been described in a recent article [2] .

Using stratified Cox regression models, we estimated hazard ratios (HRs) of hospital admission and hospital admission or emergency care attendance within 14 days, and of COVID-19 or all-cause mortality within 28 days after a first positive COVID-19 test. These models were stratified for week of specimen and lower tier local authority of residence, to account for reporting delays and unobserved confounders that may differ by calendar time and locality. Regression adjustment was A c c e p t e d M a n u s c r i p t used for age and index of multiple deprivation rank (each modelled using restricted cubic splines with 4 knots), date of specimen (linear term), sex, ethnicity, vaccination status and recent international travel. We additionally estimated the HRs within subgroups based on symptom or vaccination status. In supplementary analyses, we explored the sensitivity of the HRs to alternative adjustment approaches and to bias due to differences of epidemic phase of the sub-lineages [3] .

This surveillance was performed as part of UK Health Security Agency's (UKHSA) responsibility to monitor COVID-19 during the current pandemic. UKHSA has legal permission, provided by Regulation Tables 3-4) , consistent with the primary analysis.

Based on record linkage of sequencing-confirmed COVID-19 cases in England, we found that the risks of hospitalisation and mortality outcomes were similar or lower for cases infected with the AY.4.2 compared to non-AY.4.2 sub-lineages of the Delta variant of SARS-CoV-2. The results were similar when restricted to symptomatic and likely symptomatic cases, or to vaccinated or unvaccinated subgroups, or after additional adjustment for time since second vaccine dose. Further sensitivity analyses to adjust for the effect of epidemic phase bias [3] consistently suggested that the risks of the hospitalisation outcomes are similar or lower for AY.4.2 than non-AY.4.2 Delta cases.

Strengths of this analysis include the use of timely population datasets which cover all hospitalisation events and deaths for COVID-19 cases in England. Limitations include reporting delays of the outcome events, which may differ over time and by hospital trust. However, after stratification for calendar period and area, the reporting delays should not differ systematically by sub-lineage. A further limitation is the restriction to cases confirmed through sequencing, due to a A c c e p t e d M a n u s c r i p t lack of other methods capable of distinguishing different Delta sub-lineages. During the study period, the median daily sequencing coverage of new COVID-19 cases was 16.5% (range 6.5%-27.2%) [1] . More severe cases with higher viral loads may be preferentially selected for sequencing, which may restrict the generalisability of the findings. However, similar Ct counts were reported between individuals infected with AY.4.2 or non-AY.4.2 identified in the REACT-1 random testing survey [4] .

Hence, there is no reason to expect that such selection differed systematically by sub-lineage.

Several variants of the SARS-CoV-2 virus have evolved during the COVID-19 pandemic of 2020-2022.

In England, the Alpha (Pango lineage B.1.1.7) variant was detected in November 2020 and was found to be associated with higher transmissibility [5] , and higher risks of hospital admission [6, 7] and mortality [6, 8] , than previously circulating wildtype SARS-CoV-2. In March 2021, the Delta variant was detected in England and soon became the dominant variant in the country. Delta is associated with higher transmissibility [9] , partial vaccine escape [10, 11] , and higher risk of hospitalisation [2, 10, 12] and mortality [12] , compared to the Alpha variant. Recently, cases with AY.4.2 were reported to be less likely to experience symptomatic disease than cases with other Delta sub-lineages [4] .

Although our results indicated similar proportions with symptomatic disease in AY.4.2 and non-AY.4.2 cases, a lower propensity to cause symptomatic disease is consistent with the findings of lower severity risk with AY.4.2. Some preliminary analyses suggest that AY.4.2 might have a small transmission advantage, with 15% higher growth rate and reproduction number compared to non-AY.4.2 Delta [1, 13] . Preliminary analyses also suggest that the available vaccines are equally efficient [14] and equally effective against symptomatic disease and hospitalisation [1] dominant in England and much of the world. Omicron has been found to be associated with lower hospitalisation and mortality risks than Delta [15] . Similarly to the emergence of the AY.4.2 Delta M a n u s c r i p t sub-lineage, an Omicron sub-lineage (BA.2) with a potential transmission advantage has recently been identified [1] . The findings in our study highlight the importance of assessing severity differences between SARS-CoV-2 variant sub-lineages, and provide a baseline for future research on the relative severity between Delta or Delta variant sub-lineages and other circulating variants such as Omicron and its sub-lineages. M a n u s c r i p t A c c e p t e d M a n u s c r i p t 

SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefings

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

Adjusting for time of infection or positive test when estimating the risk of a post-infection outcome in an epidemic. medRxiv

REACT-1 round 15 final report: Increased breakthrough SARS-CoV-2 infections among adults who had received two doses of vaccine, but booster doses and first doses in children are providing important protection

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis

Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario

SARS-CoV-2 lineage dynamics in England from

high diversity of Delta sub-lineages and increased transmissibility of AY

Neutralisation of the SARS-CoV-2 Delta variant sub-lineages AY.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera

Comparative Analysis of the Risks of Hospitalisation and Death Associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) Variants in England

A c c e p t e d M a n u s c r i p t